2023
Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”
Fesharaki-Zadeh A, Lowe N, Arnsten A. Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”. Neuroimmunology Reports 2023, 3: 100154. DOI: 10.1016/j.nerep.2022.100154.Peer-Reviewed Original ResearchN-acetylcysteineCognitive deficitsΑ2A-adrenoceptor agonistsPrefrontal cortexCOVID19 infectionPlacebo-controlled trialOpen-label treatmentCommon side effectsExecutive functionPFC connectionsBrain fogAcid blockadeLabel treatmentHypotensive episodesGuanfacine treatmentNMDA receptorsPatient brieflySide effectsClinical experienceGuanfacineCognitive impairmentPatientsPrefrontal connectivityDemonstrate efficacyPrefrontal function
2022
Oxidative Stress in Traumatic Brain Injury
Fesharaki-Zadeh A. Oxidative Stress in Traumatic Brain Injury. International Journal Of Molecular Sciences 2022, 23: 13000. PMID: 36361792, PMCID: PMC9657447, DOI: 10.3390/ijms232113000.Peer-Reviewed Original ResearchConceptsTraumatic brain injuryAntioxidant therapyBrain injuryClinical settingPost-traumatic brain injuryOxidative stressReactive oxygen speciesUnderlying pathophysiological mechanismsSecondary injury cascadePromising treatment optionLipid peroxidation productsFree radical generating enzymesReal clinical settingNeurometabolic cascadeFree radical scavengerInjury cascadeChronic inflammationPathophysiological mechanismsSynaptic dysfunctionPost injuryTreatment optionsTBI treatmentSide effectsTBI symptomsInjury